


Phelan McDermid Syndrome

Thomas Bourgeron,
Institut Pasteur, France
(thomasb@pasteur.fr)





Clinical team, Robert Debré Hospital **INOVAND**
 Excellence Center for Autism and Neurodevelopmental Disorders








R. Delorme
Head of unit

A. Ayrolles, A. Maruani
Psychiatrists

M. Rachid, AC. Tabet
Cytogeneticists

R. Bonicel
Engineer

Autistic individuals, their families and non-autistic individuals



Assistant **Head of unit** **Project/data managers**













B. Devauchelle

T. Bourgeron







S. Dauzet C. Lehoucq A. Batut

Mouse models **Genetics and brain imaging**



S. Coquerant F. de Chaumont
Technician Engineer

E. Barthome F. Cliquet M. Fleury C. Leblond
PhD student Engineer Postdoc Scientist

B. Forget E. Verpy
Postdoc Scientist

N. Lemièrre A. Mathieu T. Rolland A. Vitrac
Technician Engineer Scientist Postdoc

Phelan-McDermid Syndrome INTERNATIONAL REGISTRY

the **SHANK2** foundation




AIMS2TRIALS
AUTISM RESEARCH FOR EUROPE

CANDY


ITHACA

R2D2
Mental Health







Human genome




1980




1990



2000



2010





Genetic variations

SNP



(single nucleotide polymorphism)




CNV



(copy number variant)

...tttctccatttgtcgtgac
acacaaaatatggccgtggcc
tgtgtttccatgtgtctgggct
ttactctacagccctttataaa
tactgtagttttataagtcatg
atatactttgtattgccacata
agaatctatagattaattagag
caacacccacccccactcggd
caagtccatataaaatgccatactatttgcatataacctctgcaatcctcccctatagttagatcatctctagattacttat
aatactaataaaaatctaaatgctatgta
tttggtttgtattttaagagatggtgtct
aaactcctggactcaaacagtcctcca
tttttttttttttttttttttttttt
attt
tttt
agag
tgto
caaa
tgct
gtaf
cccf
ggtt
ttgt
ccto



ctatttcactgggtctatggcagaga
cattttactaacatagccattccca
gcagagaccacaatgcctcaaatat
tatgcaataaccatactgtctttat
atcaaaagtgttttggccatcctag
catgctaggattttgtagaggattt
tattcgtgggggattggttccacaa
ctgctaccaaaatccatggatgct
gttttttgggtttggtttggttttattggtttg
cagtggtgagatcatagcttactgcagcctc
tacagggtgagaccactgtgcccagttatta
aattct
gtaaca
tgtagc
tcatta
ttaa
atagca
ccctct
ttttc
cctata
ggttt
aacagt
acg...









Synaptic signaling and spinogenesis



Genetic cocktail/orchestra




Phelan-McDermid Syndrome



Katy Phelan

Interstitial 22q13 deletion



Phelan *et al.*
Orphanet Journal of Rare Diseases (2022) 17:27
<https://doi.org/10.1186/s13023-022-02180-5>

Orphanet Journal of
 Rare Diseases

LETTER TO THE EDITOR

Open Access

Phelan-McDermid syndrome: a classification system after 30 years of experience




Katy Phelan^{1*}, Luigi Boccuto², Craig M. Powell³, Tobias M. Boeckers⁴, Conny van Ravenswaaij-Arts⁵, R. Curtis Rogers⁶, Carlo Sala⁷, Chiara Verpelli⁷, Audrey Thurm⁸, William E. Bennett Jr.⁹, Christopher J. Winrow¹⁰, Sheldon R. Garrison¹¹, Roberto Toro¹² and Thomas Bourgeron^{12*}



Katy Phelan

Classification :

- PMS *SHANK3* related
- PMS *SHANK3* unrelated



Phelan *et al.*
Orphanet Journal of Rare Diseases (2022) 17:27
<https://doi.org/10.1186/s13023-022-02180-5>

Orphanet Journal of
 Rare Diseases

LETTER TO THE EDITOR

Open Access


Phelan-McDermid syndrome: a classification system after 30 years of experience

Katy Phelan^{1*}, Luigi Boccuto², Craig M. Powell³, Tobias M. Boeckers⁴, Conny van Ravenswaaij-Arts⁵, R. Curtis Rogers⁶, Carlo Sala⁷, Chiara Verpelli⁷, Audrey Thurm⁸, William E. Bennett Jr.⁹, Christopher J. Winrow¹⁰, Sheldon R. Garrison¹¹, Roberto Toro¹² and Thomas Bourgeron^{12*}






Phelan-McDermid Syndrome







Phelan-McDermid Syndrome

Why *SHANK3* is important
for Phelan McDermid syndrome...






Mutations of the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders

Durand *et al. Nature Genetics*, 2007



trends in Cell Biology




ARTICLE OPEN




A recurrent *SHANK3* frameshift variant in Autism Spectrum Disorder


Livia O. Loureiro^{1,27}, Jennifer L. Howe^{1,27}, Miriam S. Reuter^{1,2}, Alana Iaboni³, Kristina Calli^{1,4}, Delnaz Roshandel¹, Iva Pritišanac^{5,6}, Alan Moses⁶, Julie D. Forman-Kay^{5,7}, Brett Trost¹, Mehdi Zarrei¹, Olivia Rennie¹, Lynette Y. S. Lau⁸, Christian R. Marshall^{1,8,9}, Siddharth Srivastava¹⁰, Brianna Godlewski¹⁰, Elizabeth D. Buttermore¹⁰, Mustafa Sahin¹⁰, Dean Hartley¹¹, Thomas Frazier¹², Jacob Vorstman^{13,14}, Stelios Georgiades¹⁵, Suzanne M. E. Lewis⁴, Peter Szatmari^{13,14,16}, Clarissa A. (Lisa) Bradley¹, Anne-Claude Tabet^{1,7,18}, Marjolaine Willems¹⁹, Serge Lumbroso²⁰, Amélie Piton^{21,22,23}, James Lespinasse¹⁹, Richard Delorme^{17,24}, Thomas Bourgeron¹⁷, Evdokia Anagnostou^{3,25} and Stephen W. Scherer^{1,26}✉



Steve Scherer




Phelan-McDermid Syndrome







Phelan-McDermid Syndrome






“Resilience” and *SHANK3*



Deletion

a *de novo* NLGN2 p.P777L deleterious mutation

A



```

QUERY      -----GVGADPAE-ALRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|D2X2H8#1  -----HDAH-DLELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|D2X2J7#1  -----HDAHHDLELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|UPI00016E1BBD#1  -----HDAHHDLELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|D2X2G8#1  -----HDAHHDLELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|F1QJV3#1  -----HDAHHDMEELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|D2X2G3#1  -----HDAHHDMEELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|UPI00016E1B94#1  -----HDAHHDLELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|UPI00022B0D4B#1  TPLPSRGVHGDLPLRP-----PVCPPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|UPI00016E1B95#1  -----HDAHHDLELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|DOEWN9#1  TPLPTRGLHGDLPLRP-----PVCPPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|F1QX74#1  TPLPTRGLHGDLPLRP-----PVCPPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|UPI00017B20AD#1  TPLPSRGIHGDLPLRP-----PVCPPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|D2X2J2#1  TPLPSRGVHGDLPLRP-----PVCPPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|D2X2G1#1  TPLPTRGLHGDLPLRP-----PVCPPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|UPI00016E9AAA#1  TPLPSRGVHGDLPLRP-----PVCPPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|D2X2G7#1  TPLPSRGVHGDLPLRP-----PVCPPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
sp|F1O9C0#1  -----HDAHHDMEELRPHD-ILRPACPDYTLALRRAPDDVPLLA-----PFGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
  
```

```

NL1  719 YKDKRRHDVHRRCSQQR-----TT-TNDLTHA-----PEEEIMSLQMKHTDLDHECESIHPHEV 772
NL2  700 YKRDRRQELRCRRLS-----PPGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
NL3  731 YKDKRRQEPRLRQPSQQR-----GTGAPELGT-----PEEELAAALQLGPTH--HECEAGPPHD 783
NL4  783 YKDKRRHETHRRPPPPRPPQAPPSAAAADRNRPRDPGPAGRRGGECGAVVTAMA---AEASAGGLGHDGVG-GVGVGGV1GGVA 863
  
```

gephyrin-binding

PDZ-binding

```

NL1  773 VLRTACPDYTLALRRAPDDVPLLA-----PNTITMIPNTIPG-----IQPLHTFNTFTGGQ-----NNTLPHPHPHSHSTTRV 843
NL2  761 ALRPACPDYTLALRRAPDDVPLLA-----PGALTLPSGLGPPPPPPPSLHPFPGFPFPPPPPTATSH-NNTL-----PHPHSTTRV 836
NL3  784 -LRLTALPDYTLTLRRSPDDIPLMT--PNTITMIPNSLVG-----LQTLHEYNTFAAGF-----NSTG-----LPHSHSTTRV 848
NL4  864 GLRLACPDYALTLRRSPDDVPLLA-----FRAGAGPGTMTLIPGALGGG---GGAVHGNTFGSGVGVAGVAVGAVTSQAGPGLPHGHSTTRV 945
  
```








Phelan-McDermid Syndrome

Why *SHANK3* is important for
Phelan McDermid syndrome ...

.... but, other genes are also important !



Aline Vitrac



European Journal of Medical Genetics 66 (2023) 104732




Contents lists available at ScienceDirect
European Journal of Medical Genetics

journal homepage: www.elsevier.com/locate/ejmg




Dissecting the 22q13 region to explore the genetic and phenotypic diversity of patients with Phelan-McDermid syndrome

Aline Vitrac^{a,*}, Claire S. Leblond^a, Thomas Rolland^a, Freddy Cliquet^a, Alexandre Mathieu^a, Anna Maruani^b, Richard Delorme^b, Michael Schön^c, Andreas M. Grabrucker^{d,e,f}, Conny van Ravenswaaij-Arts^g, Katy Phelan^h, Anne-Claude Tabetⁱ, Thomas Bourgeron^{d,i,*}








Aline Vitrac



A FIRST HIT SECOND *DE NOVO* HIT





N= 1,762 genes for epilepsy
 Median number of variants: 2.5
 Individuals with epilepsy **Yes** **No**




P=0.17









10/35 patients with corpus callosum (28%)



Mouse models (SHANK3)




AT Ferhat









Sabrina Coquerant



Benoit Forget



Lisa Verpy





Live Mouse Tracker

Sharing tracking mouse databases

[About](#) [Sign Up](#) [Login](#)


nature
biomedical engineering



Fabrice de Chaumont



Elodie Ey




De Chaumont, Ey *et al.*
Nature Medical Bioengineering, 2019



Fabrice de Chaumont Elodie Ey


LMT - Live 3D rendering client demo



The tracking sends all tracking information in real-time to any third-party application

Here we present an example of application:

a live 3D rendering from the point of view of mice (made with unreal engine)




The player also sends information to connected systems for test purposes






Live Mouse Tracker (LMT)




Fabrice de Chaumont



Elodie Ey



A Combination of Multi-Electrode Array (MEA) And Live Mouse Tracker (LMT) As a Versatile Drug Screening Platform for Fragile X Syndrome



Frank Kooy, PhD
Principal Investigator

Mathijs van der Lei
FRAXA Fellow

University of Antwerp
Antwerpen, Belgium

2022-2023 Grant Funding: \$100,000


Summary

Many experts believe that combinations of drugs may be needed to best treat Fragile X syndrome.


How can we find the best combinations in the ideal doses? This project -- a collaboration between a top university research team and an innovative AI startup both based in Belgium -- tackles this challenge.




Albane Imbert



De Chaumont, Ey *et al.*
Nature Medical Bioengineering, 2019








Gina G. Turrigiano

CellPress

Neuron

Report Autism-Associated Shank3 Is Essential for Homeostatic Compensation in Rodent V1

Vedakumar Tatavarty,^{1,2} Alejandro Torrado Pacheco,¹ Chelsea Groves Kuhnle,¹ Heather Lin,^{1,4} Priya Koundinya,¹ Nathaniel J. Miska,^{1,2} Keith B. Hengen,^{1,2} Florence F. Wagner,¹ Stephen D. Van Hooser,¹ and Gina G. Turrigiano^{1,2,*}



Screening

Toxicity

% of neurons

Alexandra Benchoua

Lithium
Li
6.94

Tobias Boeckers

A




SHANK3 + NEFH

MN SHANK3

C

SHANK3 + α -ACTININ

Myotubes SHANK3



Screening

Toxicity

Alexandra Benchoua

Tobias Boeckers

A SHANK3 + NEPH

B MN SHANK3

C SHANK3 + α-ACTININ

D Myotubes SHANK3


LISPHEM : 16/22 patients included !



Richard Delorme



Anna Maruani




Anne Claude Tabet

Phelan McDermid Syndrome in Europe



Prof Conny van Ravenswaaij-Arts



European effort on PMS/SHANK3 and clinical trials



Merci !





@thomas.bourgeron

Postdoctoral positions available !!






ghfc1@pasteur.fr

“Resilience” and *SHANK3*



a *de novo* NLGN2 p.P777L deleterious mutation

A



```

QUERY -----GVGADPAE-ALRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|D2X2H8#1 -----HDAH-DLELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|D2X2J7#1 -----HDAHHDLELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|UPI00016E1BBD#1 -----HDAHHDLELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|D2X2G8#1 -----HDAHHDLELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|F1QJV3#1 -----HDAHHDMELELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|D2X2G3#1 -----HDAHHDMELELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|UPI00016E1B94#1 -----HDAHHDLELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|UPI00022B0D4B#1 TPLPSRGVHGDLPLRP-----PVCPPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|UPI00016E1B95#1 -----HDAHHDLELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|DOEWN9#1 TPLPTRGLHGDLPLRP-----PVCPPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|F1QX74#1 TPLPTRGLHGDLPLRP-----PVCPPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|UPI00017B20AD#1 TPLPSRGIHGDLPLRP-----PVCPPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|D2X2J2#1 TPLPSRGVHGDLPLRP-----PVCPPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|D2X2G1#1 TPLPTRGLHGDLPLRP-----PVCPPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|UPI00016E9AAA#1 TPLPSRGVHGDLPLRP-----PVCPPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|D2X2G7#1 TPLPSRGVHGDLPLRP-----PVCPPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
sp|F1O9C0#1 -----HDAHHDMELELRPHD-ILRPACPDYTLARRA-IVL- -LAPGALLPGLGPPPPPPPSLHPFQPF
  
```

```

NL1 719 YKDKRRHDVHRRCSQQR-----TT-TNDLTHA-----PEEEIMSLQMKHTDLDHECESIHPHEV 772
NL2 700 YKRDRRQELRCRRLS-----PPGGSGSGVPGGGPLLPTAGR-----ELPPEEELVSLQLKRGH-GVGADPA----E 760
NL3 731 YKDKRRQEPRLRQPSQQR-----GTGAPELGT-----PEEELAAALQLGPTH--HECEAGPPHD 783
NL4 783 YKDKRRHETHRRPPPPRPPQAPPSAAAADRNRPRDPGPAGRRGGECGAVVTAMA---AEASAGGLGHDGVG-GVGVGGV1GGVA 863
  
```

gephyrin-binding

PDZ-binding

```

NL1 773 VLRTACPDYTLAMRRSPDDIPLMT--PNTITMIPNTIPG-----IQPLHTFNTFTGGQ-----NNTLPHPHPHSHSTTRV 843
NL2 761 ALRPACPDYTLALRRAPDDVPLLA--PGALLPGLGPPPPPPPSLHPFQPFPPPTATSH-NNTL-----PHPSHSTTRV 836
NL3 784 -LRLTALPDYTLTLRRSPDDIPLMT--PNTITMIPNSLVG-----LQTLHEYNTFAAGF-----NSTG-----LPHSHSTTRV 848
NL4 864 GLRLACPDYALTLRRSPDDVPLRAGAGPGTMTLIPGALGGG---GGAVHGNTFGSGVGVAGVAVTSQAGPGLPHGSHSTTRV 945
  
```







Merci !




GHFC











SHANKOPATHIES



Patients with *SHANK2* mutations



	Del_exon 6-7 Pinto et al. 2010	Del_exon 14-15 Pinto et al. 2010	Del_exon 4-15 Leblond et al. 2012	Del_11q13.3q13.4 This study	t(1;7;11)(p35;q33;q12)dn This study	Del_11q13.2q13.4 Wischmeijer et al. 2010
SHANK2						
A	<ul style="list-style-type: none"> Autism Early DD (mild motor & language delay) Mild ID / verbal 	<ul style="list-style-type: none"> Autism Early DD (mild motor & language delay) Mild ID / verbal Neonatal hypotonia 	<ul style="list-style-type: none"> Autism Early DD (mild motor & language delay) Mild ID /verbal 	<ul style="list-style-type: none"> Autism Global DD Severe ID / non verbal 	<ul style="list-style-type: none"> Autism Global DD Severe ID / non verbal Neonatal hypotonia 	<ul style="list-style-type: none"> Autism Global DD Severe ID / non verbal Neonatal hypotonia
B	<ul style="list-style-type: none"> Large ears Long eyelashes Wide nasal bridge Clinodactyly(5th fingers) 	<ul style="list-style-type: none"> Large ears Pointed chin Wide nasal bridge Retrognathia 	<ul style="list-style-type: none"> Deepset eyes Large ears Pointed chin Wide nasal bridge Retrognathia Thin upper lip Clinodactyly(5th fingers) 	<ul style="list-style-type: none"> Deepset eyes Strabism & ptosis # Large ears Wide nasal bridge Retrognathia Thin upper lip Clinodactyly(5th fingers) 	<ul style="list-style-type: none"> Deepset eyes, epicanthus Large ears Long eyelashes Wide nasal bridge Retrognathia Clinodactyly(5th fingers) Clinodactyly(5th fingers) 	<ul style="list-style-type: none"> Deepset eyes, epicanthus Long eyelashes, ptosis Wide nasal bridge Retrognathia Thin upper lip Clinodactyly (5th fingers) & syndactylia (2nd - 3rd)
C		<ul style="list-style-type: none"> Slight hypotonia Oral dyspraxia Signs of cerebellar dysfunction (dysmetria, dysdiadochokinesia) 	<ul style="list-style-type: none"> Slight hypotonia Oral dyspraxia Signs of cerebellar dysfunction (dysmetria, dysdiadochokinesia) 	<ul style="list-style-type: none"> Hypotonia Oral dyspraxia Signs of cerebellar dysfunction (dysmetria, dysdiadochokinesia) 		<ul style="list-style-type: none"> Hypotonia Oral dyspraxia

Patients with *SHANK3* mutations

	P1005Rfs*73 This study	G1339Efs*5 This study	E809X This study	S1202Cfs*81 This study	Q1243X This study	L1142Vfs*153 This study
SHANK3						
A	<ul style="list-style-type: none"> Autism Global DD Severe ID/non verbal Early regression 	<ul style="list-style-type: none"> Autism Global DD Severe ID/non verbal Late regression 	<ul style="list-style-type: none"> Autism Global DD Moderate ID/ verbal Early regression 	<ul style="list-style-type: none"> Autism Global DD Moderate ID/verbal Early regression 	<ul style="list-style-type: none"> Autism Global DD Severe ID/non verbal 	<ul style="list-style-type: none"> Autism Global DD Severe ID/non verbal Early regression
B	<ul style="list-style-type: none"> Large ears Long eyelashes Wide nasal bridge Smoothing philtrum 	<ul style="list-style-type: none"> Long face Long eyelashes Deep-set eyes Smoothing philtrum Prognathia Dysplastic toe nails 	<ul style="list-style-type: none"> Large detached ears Bulbous nose Pointed chin Retrognathia 		<ul style="list-style-type: none"> Large ears Long eyelashes Deep-set eyes Wide nasal bridge Strabism Dental malocclusion 	<ul style="list-style-type: none"> Large ears Puffy eyelids Deep-set eyes Wide nasal bridge Bulbous nose Pointed chin
C	<ul style="list-style-type: none"> Hypotonia 	<ul style="list-style-type: none"> Hypotonia Ataxia, dysmetria 	<ul style="list-style-type: none"> Hypotonia 		<ul style="list-style-type: none"> Hypotonia 	<ul style="list-style-type: none"> Severe stereotypies
D	<ul style="list-style-type: none"> Cycling vomiting 	<ul style="list-style-type: none"> GO reflux Seizures Chewing non-food items 	<ul style="list-style-type: none"> Cholesteatoma 	<ul style="list-style-type: none"> Migraines Seizures 	<ul style="list-style-type: none"> GO reflux 	<ul style="list-style-type: none"> Scoliosis Seizures



Synaptic cocktail / orchestra



<http://gravity.pasteur.fr/>